JPH03115276A - 抗腫瘍抗生物質ｂｕ―３２８５ｔ - Google Patents

抗腫瘍抗生物質ｂｕ―３２８５ｔ

Info

Publication number
JPH03115276A
JPH03115276A JP2183875A JP18387590A JPH03115276A JP H03115276 A JPH03115276 A JP H03115276A JP 2183875 A JP2183875 A JP 2183875A JP 18387590 A JP18387590 A JP 18387590A JP H03115276 A JPH03115276 A JP H03115276A
Authority
JP
Japan
Prior art keywords
desulfate
tumor
formula
host
tables
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2183875A
Other languages
English (en)
Other versions
JPH0684366B2 (ja
Inventor
Hiroaki Ohkuma
大熊　広昭
Koji Tomita
富田　康二
Masataka Konishi
小西　正隆
Hideo Kamei
亀井　英夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JPH03115276A publication Critical patent/JPH03115276A/ja
Publication of JPH0684366B2 publication Critical patent/JPH0684366B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。

Description

【発明の詳細な説明】 発明の背景 （１）発明の分野 本発明は新規抗腫瘍抗生物質、Ｂ　Ｕ　−３２８５Ｔ、
および属カイニア（（：ｈａｉｎｉａ）に属する微生物
の培養によりそれを製造する方法に関する。この化合物
は高水準の抗腫瘍活性を示し、また抗真菌活性を有する
。本発明はまた一定のスルファターゼ酵素によるＢ　Ｕ
−３２８５Ｔのスルフアート結合の酵素開裂により得ら
れるＢ　Ｕ−３２８５Ｔデスルフアートに関する。デス
ルファート誘導体は抗腫瘍活性を有する。
（２）従来技術の説明

Claims (1)

  1. 【特許請求の範囲】 （１）構造式： ▲数式、化学式、表等があります▼ を有する化合物ＢＵ−３２８５Ｔ。 （２）式： ▲数式、化学式、表等があります▼ を有するＢＵ−３２８５Ｔを製造する方法であって、カ
    イニア・ロセア（Ｃｈａｉｎｉａｒｏｓｅａ）のＢＵ−
    ３２８５Ｔ産生株を、炭素および窒素の同化可能源を含
    む水性普通培地中で液内好気性条件下に実質量のＢＵ−
    ３２８５Ｔが前記培地中の前記生物体により生産される
    まで培養し、次いで培地から実質的に共生物質を含まな
    いＢＵ−３２８５Ｔを回収することを含む方法。 （３）ＢＵ３２８５−Ｔ産生株がカイニア・ロセア（Ｃ
    ｈａｉｎｉａｒｏｓｅａ）ＡＴＣＣ−５３９０３あるい
    はその突然変異体または変異体である、請求項（２）記
    載の方法。（４）炭素の同化可能源を含む水性普通培地
    中で液内好気性条件下に培養すると抗生物質ＢＵ−３２
    ８５Ｔを生ずることができる微生物カイニア・ロセア（
    Ｃｈａｉｎｉａｒｏｓｅａ）ＡＴＣＣ−５３９０３の生
    物学的に純粋な培養株あるいはＢＵ−３２８５Ｔ産生の
    特徴を保持するカイニア・ロセア（Ｃｈａｉｎｉａｒｏ
    ｓｅａ）ＡＴＣＣ−５３９０３の変異体または突然変異
    体。 （５）請求項（１）記載のＢＵ−３２８５Ｔ治療有効量
    および薬学的担体を含む、真菌感染により罹患した動物
    宿主の治療処置に用いる薬学的組成物。 （６）ＢＵ−３２８５Ｔ腫瘍阻止量および薬学的担体を
    含む、請求項（１）記載のＢＵ−３２８５Ｔに感受性の
    腫瘍により罹患した哺乳動物宿主の治療処置に用いる薬
    学的組成物。 （７）請求項（１）記載のＢＵ−３２８５Ｔ抗真菌有効
    量を宿主に投与することを含む、真菌感染により罹患し
    た動物宿主を治療的に処置する方法。 （８）ＢＵ−３２８５Ｔを腫瘍の阻止に有効な量宿主に
    投与することを含む、請求項（１）記載のＢＵ−３２８
    ５Ｔに感受性の腫瘍により罹患した哺乳動物宿主を治療
    的に処置する方法。 （９）式： ▲数式、化学式、表等があります▼ を有するＢＵ−３２８５Ｔデスルファートと称される化
    合物。 （１０）式： ▲数式、化学式、表等があります▼ のＢＵ−３２８５Ｔデスルファートを製造する方法であ
    って、式： ▲数式、化学式、表等があります▼ の抗生物質ＢＵ−３２８５Ｔを、ＢＵ−３２８５Ｔを所
    望ＢＵ−３２８５Ｔデスルファート誘導体に転化できる
    スルファターゼ酵素と反応させることを含む方法。 （１１）ＢＵ−３２８５Ｔデスルファート腫瘍阻止量お
    よび薬学的担体を含む、請求項（９）記載のＢＵ−３２
    ８５Ｔデスルファートに感受性の腫瘍により罹患した哺
    乳動物宿主の治療処置に用いる薬学的組成物。 （１２）ＢＵ−３２８５Ｔデスルファートを腫瘍の阻止
    に有効な量宿主に投与することを含む、請求項（９）記
    載のＢＵ−３２８５Ｔデスルファートに感受性の腫瘍に
    より罹患した哺乳動物宿主を治療的に処置する方法。
JP2183875A 1989-07-12 1990-07-11 抗腫瘍抗生物質ｂｕ―３２８５ｔ Expired - Lifetime JPH0684366B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US37867789A 1989-07-12 1989-07-12
US378677 1989-07-12
US431423 1989-11-03
US07/431,423 US4952709A (en) 1989-07-12 1989-11-03 Antitumor antibiotic BU-3285T compounds

Publications (2)

Publication Number Publication Date
JPH03115276A true JPH03115276A (ja) 1991-05-16
JPH0684366B2 JPH0684366B2 (ja) 1994-10-26

Family

ID=27008309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2183875A Expired - Lifetime JPH0684366B2 (ja) 1989-07-12 1990-07-11 抗腫瘍抗生物質ｂｕ―３２８５ｔ

Country Status (13)

Country Link
US (1) US4952709A (ja)
EP (1) EP0408336B1 (ja)
JP (1) JPH0684366B2 (ja)
KR (1) KR930005868B1 (ja)
AT (1) ATE111091T1 (ja)
AU (1) AU617950B2 (ja)
CA (1) CA2020878C (ja)
DE (1) DE69012245T2 (ja)
DK (1) DK0408336T3 (ja)
ES (1) ES2060957T3 (ja)
FI (1) FI95286C (ja)
IE (1) IE64853B1 (ja)
PT (1) PT94670B (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100786785B1 (ko) * 2006-11-27 2007-12-18 한국생산기술연구원 저공해 예혼합 연소기

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4578383A (en) * 1982-12-07 1986-03-25 Warner-Lambert Company CL 1565 antibiotic compounds
US4680416A (en) * 1983-05-12 1987-07-14 Warner-Lambert Company Antibiotic CL-1565 complex derivatives
EP0128651A3 (en) * 1983-05-12 1987-01-07 Warner-Lambert Company Pyranones and related compounds and methods for their production and use
US4495286A (en) * 1983-05-25 1985-01-22 Warner-Lambert Company Antibiotic complex producing bacterial culture
CA1232852A (en) * 1983-09-12 1988-02-16 Gerard C. Hokanson Cl-1957b antibiotic compound and its production
US4792522A (en) * 1983-12-12 1988-12-20 Bristol-Myers Company Rigolettone antitumor complex

Also Published As

Publication number Publication date
PT94670B (pt) 1997-07-31
CA2020878C (en) 1996-06-18
EP0408336A3 (en) 1991-04-03
CA2020878A1 (en) 1991-01-13
DK0408336T3 (da) 1994-10-10
EP0408336A2 (en) 1991-01-16
ES2060957T3 (es) 1994-12-01
IE902535A1 (en) 1991-02-13
JPH0684366B2 (ja) 1994-10-26
FI95286C (fi) 1996-01-10
FI903459A0 (fi) 1990-07-09
FI95286B (fi) 1995-09-29
DE69012245D1 (de) 1994-10-13
KR920002791A (ko) 1992-02-28
PT94670A (pt) 1991-03-20
ATE111091T1 (de) 1994-09-15
AU5892890A (en) 1991-01-17
AU617950B2 (en) 1991-12-05
US4952709A (en) 1990-08-28
DE69012245T2 (de) 1995-01-05
IE64853B1 (en) 1995-09-06
KR930005868B1 (ko) 1993-06-25
EP0408336B1 (en) 1994-09-07

Similar Documents

Publication Publication Date Title
HU913396D0 (en) Process for the production of azasteroide compounds and medical preparations containing them as active agents
JPS5886093A (ja) アミドの生物学的製造法
JPS5925599B2 (ja) 新生理活性物質モナコリンｋおよびその製造法
KR840007257A (ko) 레베카마이신과 그것의 제조방법
KR920006360A (ko) 스쿠알렌 합성효소 억제제
AU669584B2 (en) Process for preparation of indolopyrrolocarbazole derivatives
Park et al. SN transfer and dual acetylation in the S-acetylation and N-acetylation of 3-phosphoglyceraldehyde dehydrogenase by substrates
JPH0751064B2 (ja) 新規なヒアルロニダ−ゼｓｄ−６７８およびその製造法
JPH03115276A (ja) 抗腫瘍抗生物質ｂｕ―３２８５ｔ
JPS611384A (ja) Ｎ−アセチルノイラミン酸リア−ゼの製法
CA1245589A (en) Indanyl derivatives and process for their preparation
US5041423A (en) Antibiotics of the mureidomycin group, their preparation, and their therapeutic use
US3975235A (en) Process for the production of cephamycin type antibiotic substances
US3823069A (en) Preparation of l(-)-ypsilon-amino-alpha-hydroxybutyric acid
DE3562623D1 (en) 2'-chloropentostatin, a pharmaceutical composition comprising the compound and a novel microorganism for producing the compound
KR910014398A (ko) 항생제 데옥시물룬도칸딘, 이의 제조방법 및 약제로서의 이의 용도
IL83225A (en) Antibiotic a 42867,process for its production and pharmaceutical compositions containing it
US4950605A (en) FR-900493 substance, a process for its production and a pharmaceutical composition containing the same
JPH03218394A (ja) 抗腫瘍抗生物質ｂｕ―３９８３ｔ
KR910014509A (ko) 항생성 알리사마이신, 이의 제조방법 및 용도
SU763464A1 (ru) Способ получени над-зависимой алкогольдегидрогеназы
JPH0625183A (ja) 生理活性物質ｂｅ−１９０９３及びその製造法
KR860002574A (ko) 항생물질 at 2433 복합체의 제조방법
EP0133550A2 (en) Process for producing arphamenine in high yield
JPS6255098A (ja) 光学活性α−オキシ酸の製造法

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20071026

Year of fee payment: 13

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20081026

Year of fee payment: 14

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091026

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20091026

Year of fee payment: 15

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101026

Year of fee payment: 16

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20101026

Year of fee payment: 16